

S 689

A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.

Congress: 118 (2023–2025, Ended)

Chamber: Senate

Policy Area: Crime and Law Enforcement

Introduced: Mar 7, 2023

Current Status: Read twice and referred to the Committee on the Judiciary.

Latest Action: Read twice and referred to the Committee on the Judiciary. (Mar 7, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/senate-bill/689>

Sponsor

Name: Sen. Booker, Cory A. [D-NJ]

Party: Democratic • **State:** NJ • **Chamber:** Senate

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Paul, Rand [R-KY]	R · KY		Mar 7, 2023
Sen. Braun, Mike [R-IN]	R · IN		Sep 11, 2023
Sen. Fetterman, John [D-PA]	D · PA		Sep 11, 2023
Sen. Boozman, John [R-AR]	R · AR		Sep 12, 2023
Sen. Sinema, Kyrsten [I-AZ]	I · AZ		May 23, 2024

Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	Senate	Referred To	Mar 7, 2023

Subjects & Policy Tags

Policy Area:

Crime and Law Enforcement

Related Bills

No related bills are listed.

Summary (as of Mar 7, 2023)

This bill provides for the classification of drugs or other substances that are part of approved breakthrough therapies as schedule II controlled substances under the Controlled Substances Act. (Schedule II controlled substances are substances that have a high potential for abuse but have a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions.)

Actions Timeline

- **Mar 7, 2023:** Introduced in Senate
- **Mar 7, 2023:** Read twice and referred to the Committee on the Judiciary.